The Next Step in Continuous Glucose Monitoring:
Making Diabetes Management Decisions with Sensor Glucose Information
with Claudio Cobelli, PhD, Andrea Facchinetti, PhD, Jan Šoupal, MD and Davida F. Kruger, MSN, APN-BC, BC-ADM


Endocrinologists, Primary Care Physicians, Nurse Practitioners, Certified Diabetes Educators and other Health Care Professionals interested in the management of diabetes.


Self-monitoring of blood glucose (SMBG) is a core component of a diabetic patient's management but only provides a measurement of blood glucose levels at a specific point in time, often missing trends, hyperglycemic or hypoglycemic excursions. HbA1c is even more limited and reports an average reading over 90 days; therefore incapable of alerting the patient of fluctuations in blood glucose at any point in time.

Selection of an appropriate CGM device is important because improvements in accuracy and reliability are ongoing. RT-CGM is one cornerstone of optimal glycemic control. Each varies; relying on different sensing technology and requiring the traditional fingerstick for confirmation of alerts. The Mean Absolute Relative Difference (MARD) between sensor readings and reference glucose levels can vary by as much as 20% with worrisome discrepancies in the hypoglycemic range. But new generation devices have significantly improved MARD measurements. These devices have shorter lag times and improvements in accuracy. Many physicians are lacking the appropriate level of knowledge to employ CGM as part of their practices. Educational programs focused on these knowledge gaps will enable healthcare professionals to provide improved patient care.

Significant improvements in accuracy of Continuous Glucose Monitoring (CGM) sensors and device algorithms have made CGM-based decisions a near-term possibility. This program will evaluate the potential clinical application and use of CGM in diabetes management decisions and the importance of various aspects of CGM to guide optimal treatment.


At the conclusion of this activity, participants should be better able to:

  1. Define the role of CGM in diabetes management treatment decisions for intensive insulin therapy patients
  2. Employ novel management strategies in personal and professional RT-CGM
  3. Identify patient types, via clinical case reports, that will most benefit from RT-CGM


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education LLC and CogniMed Inc. Evolve Medical Education LLC is accredited by the ACCME to provide continuing medical education for physicians.

Evolve Medical Education LLC designates this enduring activity for a maximum of 2.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The official release date for this activity is July 7, 2016 and the expiration date is September 15, 2018.

Statements of Credit will be provided by email following activity participation and upon completion and return of the Posttest and Evaluation Forms to CogniMed Inc. via submission at the end of the activity. Please allow 4 to 6 weeks for the delivery of your statement.


It is the policy of Evolve Medical Education, LLC to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity have disclosed that there will not be discussion about the use of products for non-FDA-approved indications. In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Evolve Medical Education LLC policy, the following disclosures have been made:

Cheryl Cavanaugh, Director of Operations, has nothing to disclose.

Jeffrey Rosenberg, Project Coordinator, has nothing to disclose.

Claudio Cobelli, PhD is Grant/Research Support for Dexcom and Roche. He is a Novo Nordisk Advisory Board/Speaker's Bureau/Consultant.

Andrea Facchinetti, PhD has nothing to disclose

Jan Šoupal, MD is a Medtronic, Roche, and Novo Nordisk Advisory Board/Speaker's Bureau/Consultant.

Davida F. Kruger, MSN, APN-BC, BC-ADM is Grant/Research Support for Dexcom, Novo Nordisk, Lilly, AZ, Medtronic, and Lexicon. She is an Animas, Dexcom, Lilly, Novo Nordisk, Boehringer Ingelheim, Janssen Pharmaceuticals, Abbott, and Sanofi Advisory Board/Speaker's Bureau/Consultant. She is a Dexcom Stock Shareholder.

Jointly provided by CogniMed Inc. and Evolve Medical Education LLC.

This activity is supported by an independent educational grant provided by Dexcom.

© 2016 CogniMed Inc. All rights reserved.

Next to Webcast